Clinical trial

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

NCT05220917

StatusACTIVE_NOT_RECRUITING

Study typeOBSERVATIONAL

Start date2021-08-01

PhaseN/A

Study timeline

Study start (actual)2021-08-01Date precision: day

Registry last updated2026-08-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Cardiovascular Eventsunresolved

Type2 Diabetesunresolved

Renal Diseaseunresolved

Interventions

SGLT2 inhibitorDRUG

DPP-4 inhibitorDRUG

2nd generation SUDRUG

Sponsors & collaborators

Brigham and Women's Hospitallead sponsor

Patient-Centered Outcomes Research Institutecollaborator

VA Boston Healthcare Systemcollaborator

McGill Universitycollaborator

Mapped research locations

BostonMassachusetts, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05220917 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.